Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects.
Journal: Diabetes, obesity & metabolism
Published: November 04, 2024
Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial.
Journal: Frontiers in immunology
Published: October 15, 2024
Randomized trial of pharmacokinetic and pharmacodynamic effects of 13.2 mg intranasal epinephrine treatment in congestion.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: February 07, 2024
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.
Journal: British journal of clinical pharmacology
Published: June 19, 2023
A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector.
Journal: The journal of allergy and clinical immunology. Global
Published: May 27, 2023
Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
Journal: Clinical pharmacology in drug development
Published: January 19, 2023
Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: January 18, 2023
Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib.
Journal: Clinical pharmacology in drug development
Published: July 27, 2022
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Journal: Clinical pharmacology in drug development
Published: July 06, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026